ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 156 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q3 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $370,000 | -5.9% | 24,948 | +0.0% | 0.00% | 0.0% |
| Q2 2022 | $393,000 | -41.5% | 24,937 | +0.0% | 0.00% | -33.3% |
| Q1 2022 | $672,000 | -27.1% | 24,936 | +0.0% | 0.00% | -25.0% |
| Q4 2021 | $922,000 | -22.6% | 24,925 | +0.0% | 0.00% | -33.3% |
| Q3 2021 | $1,191,000 | +41.3% | 24,920 | 0.0% | 0.01% | +50.0% |
| Q2 2021 | $843,000 | -18.1% | 24,920 | -0.0% | 0.00% | -33.3% |
| Q1 2021 | $1,029,000 | -9.7% | 24,925 | -5.1% | 0.01% | -14.3% |
| Q4 2020 | $1,139,000 | -6.5% | 26,266 | -7.5% | 0.01% | -12.5% |
| Q3 2020 | $1,218,000 | -12.0% | 28,396 | -4.1% | 0.01% | -20.0% |
| Q2 2020 | $1,384,000 | +244.3% | 29,600 | 0.0% | 0.01% | +233.3% |
| Q1 2020 | $402,000 | +24.8% | 29,600 | 0.0% | 0.00% | +50.0% |
| Q4 2019 | $322,000 | +5.9% | 29,600 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $304,000 | +17.8% | 29,600 | +8.4% | 0.00% | 0.0% |
| Q2 2019 | $258,000 | – | 27,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DFPG INVESTMENTS, LLC | 456,390 | $5,541,000 | 3.62% |
| DAFNA Capital Management LLC | 173,914 | $1,890,000 | 0.65% |
| One68 Global Capital, LLC | 19,861 | $216,000 | 0.47% |
| Diametric Capital, LP | 51,982 | $565,000 | 0.41% |
| ARK Investment Management | 1,383,756 | $15,041,000 | 0.38% |
| EAM Investors, LLC | 52,833 | $574,000 | 0.13% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 31,404 | $341,000 | 0.05% |
| Nikko Asset Management Americas, Inc. | 280,548 | $3,050,000 | 0.05% |
| MGO ONE SEVEN LLC | 14,900 | $161,000 | 0.04% |
| Qube Research & Technologies Ltd | 67,702 | $736,000 | 0.02% |